Gene therapy for lipid disorders

Area of Science:

• Cardiovascular Medicine
• Genetics
• Biotechnology

Background:

• Lipid disorders significantly increase the risk of atherosclerotic vascular disease and cardiovascular events.
• Current lipid disorder therapies are insufficient for a considerable patient population.
• There is a critical need for novel therapeutic strategies for refractory hypercholesterolemia, severe hypertriglyceridemia, and low high-density lipoprotein cholesterol.

Purpose of the Study:

• To explore somatic gene therapy as a viable approach for treating challenging lipid disorders.
• To highlight the well-understood molecular basis and pathophysiology of target lipid diseases.
• To underscore the readiness of the field for clinical translation, supported by animal models and preclinical data.

Main Methods:

• Review of the molecular etiology and pathophysiology of target lipid disorders.
• Assessment of existing animal models and preclinical proof-of-principle studies.
• Evaluation of advancements in vector development for sustained gene expression.

Main Results:

• The molecular underpinnings of many candidate lipid disorders are well-established.
• Preclinical evidence supports the efficacy of gene therapy in relevant animal models.
• Progress in vector technology facilitates long-term gene expression, crucial for therapeutic benefit.

Conclusions:

• Somatic gene therapy presents a viable and needed therapeutic option for difficult-to-treat lipid disorders.
• The scientific foundation and preclinical data are robust, paving the way for clinical application.
• The initiation of new clinical gene therapy trials for lipid disorders is anticipated in the near future.